Marizomib Designated Orphan Drug Status for Multiple Myeloma
Triphase Accelerator announced that the FDA has granted marizomib Orphan Drug designation for the treatment of multiple myeloma. Marizomib is a novel, highly potent proteasome inhibitor that is also being evaluated for the treatment of other cancer indications.
An intravenous (IV) formulation of marizomib has been evaluated in more than 230 patients across four Phase 1/2 studies, either as a single agent or in combination with dexamethasone or an HDAC inhibitor. Triphase is currently evaluating the IV formulation in an ongoing Phase 2 clinical trial in combination with dexamethasone in a highly refractory multiple myeloma population, including those refractory to carfilzomib. It is also being tested in a Phase 1/2 study in combination with pomalidomide and dexamethasone in relapsed and
For more information call (858) 242-1513 or visit TriPhaseCo.com.